FFTY Fact Sheet: CapForce IBD 50 ETF
Share
$27.41
close, Nov 20, 2026
Over the year to Nov 19, 2026, FFTY returned −17.5% in total and charged 0.80% a year.
- 1-year total return
- −14.9%
- to Nov 20, 2026
- Expense ratio
- 0.80%
- a year
- Net flow, since Apr 2026
- −$5.9m
- monthly N-PORT basis to Jul 31, 2026
Growth of $10,000, 1 year
FFTY $8,250 −17.5% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−17.8%
3 months−25.7%
Year to date−21.3%
1 year−14.9%
3 years+24.9%
5 years−42.6%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
Kiniksa Pharmaceuticals Intern4.24%
Guardant Health Inc3.83%
Travere Therapeutics Inc3.54%
TG Therapeutics Inc3.52%
Enova International Inc3.49%
Liquidia Corp3.44%
Okeanis Eco Tankers Corp3.26%
Oscar Health Inc3.23%
Sezzle Inc3.16%
Carpenter Technology Corp3.15%
FFTY top ten by weight, 34.9% of the fund, of its 50 equity positions, from the holdings filed for Jul 31, 2026.
Facts
Equity fund · First traded Apr 9, 2015 · Benchmark Its own holdings, as of Jul 31, 2026